U.S. Physical Therapy (USPH) – Analysts’ Recent Ratings Changes

U.S. Physical Therapy (NYSE: USPH) has recently received a number of price target changes and ratings updates:

  • 3/9/2018 – U.S. Physical Therapy had its price target raised by analysts at Cantor Fitzgerald to $90.00. They now have an “overweight” rating on the stock.
  • 3/9/2018 – U.S. Physical Therapy had its “hold” rating reaffirmed by analysts at Barrington Research. They wrote, “We are maintaining our MARKET PERFORM investment rating on USPH shares. While we really like this business and think its leadership is among the best we have seen in healthcare services, the stock’s current valuation is higher than we can ever recall in our 14 years of covering this idea. We would certainly reconsider our investment rating if shares were to weaken a bit.””
  • 3/9/2018 – U.S. Physical Therapy was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh’s clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company’s growth, are structured like the de novo partnerships, with significant ownership retained by founders. “
  • 3/7/2018 – U.S. Physical Therapy was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $89.00 price target on the stock. According to Zacks, “U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh’s clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company’s growth, are structured like the de novo partnerships, with significant ownership retained by founders. “
  • 2/23/2018 – U.S. Physical Therapy was given a new $76.00 price target on by analysts at Jefferies Group LLC. They now have a “hold” rating on the stock.

Shares of U.S. Physical Therapy, Inc. (NYSE USPH) traded up $0.45 during trading hours on Friday, reaching $83.00. The company had a trading volume of 121,727 shares, compared to its average volume of 48,727. U.S. Physical Therapy, Inc. has a 12 month low of $56.50 and a 12 month high of $87.50. The firm has a market cap of $1,038.57, a price-to-earnings ratio of 47.43, a P/E/G ratio of 3.01 and a beta of 1.16. The company has a quick ratio of 2.04, a current ratio of 1.95 and a debt-to-equity ratio of 0.28.

How to Become a New Pot Stock Millionaire

U.S. Physical Therapy (NYSE:USPH) last announced its earnings results on Thursday, March 8th. The company reported $0.49 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.49. The company had revenue of $109.20 million for the quarter, compared to analyst estimates of $104.12 million. U.S. Physical Therapy had a return on equity of 13.12% and a net margin of 5.38%. equities analysts predict that U.S. Physical Therapy, Inc. will post 2.44 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Wednesday, March 21st will be issued a $0.23 dividend. The ex-dividend date of this dividend is Tuesday, March 20th. This is a positive change from U.S. Physical Therapy’s previous quarterly dividend of $0.20. This represents a $0.92 dividend on an annualized basis and a dividend yield of 1.11%. U.S. Physical Therapy’s dividend payout ratio is currently 45.71%.

In other news, Director Bernard A. Harris, Jr. sold 6,000 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $86.53, for a total value of $519,180.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Lawrance W. Mcafee sold 5,000 shares of the stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $83.35, for a total value of $416,750.00. The disclosure for this sale can be found here. Insiders sold 21,268 shares of company stock worth $1,770,623 over the last three months. Corporate insiders own 3.10% of the company’s stock.

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.

Receive News & Ratings for US Physical Therapy Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Physical Therapy Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply